It was one of the most anticipated earnings weeks of the year. As Wall Street braced for volatility amid ongoing macroeconomic uncertainty, four of America’s most consequential companies — UnitedHealth Group (UNH), GE Aerospace (GE), 3M (MMM), and RTX (RTX) — stepped up to the plate and delivered their first-quarter 2026 results. The stakes couldn’t have been higher. Investors, analysts, and everyday Americans with 401(k)s watched closely, because these four companies don’t just move markets — they represent the backbone of U.S. healthcare, aviation, defense, and industrial manufacturing.
The results? A mixed but overwhelmingly encouraging picture. Some companies shattered expectations. Some defied narratives of decline. And at least one managed to beat the numbers while still making Wall Street nervous. Let’s break it all down — company by company, number by number — so you understand exactly what happened, what it means for your portfolio, and why this earnings week matters far beyond the trading floor.
The Week That Defined Q1 2026
Going into this week, the market was sitting at or near all-time highs after a sharp rebound from earlier-year turbulence. Analysts were cautiously optimistic, but also wary — tariff uncertainty, shifting Medicare reimbursement rates, and global defense demand were all wildly unpredictable variables. Any one of these four companies could have easily disappointed. Instead, each company delivered a positive surprise in its own way, reinforcing confidence that corporate America’s earnings engine remains intact.
This isn’t just financial theater. When UnitedHealth reports, it signals the health of American healthcare spending. When GE Aerospace and RTX beat estimates, it tells us that global aviation and defense budgets are growing. When 3M holds its guidance steady while beating profit estimates, it suggests that even beleaguered industrial conglomerates can find their footing in volatile economies. Taken together, these four reports are a quarterly pulse check on the American economy itself.
UnitedHealth Group: A Stunning Comeback Story
If you had told Wall Street analysts two quarters ago that UnitedHealth would be one of the biggest positive surprises of April 2026, many would have been skeptical. The company has been navigating rough waters — from Medicare Advantage reimbursement pressures to high medical cost ratios to lingering fallout from the Change Healthcare cyberattack. The narrative heading into Q1 2026 was cautious at best.
Then Tuesday morning happened.
UnitedHealth Group reported adjusted earnings of $7.23 per share for the first quarter of 2026, obliterating the average analyst estimate of $6.57 per share — a beat of 66 cents. The company didn’t stop there. It raised its full-year 2026 adjusted profit per share guidance to greater than $18.25, up from the prior forecast of greater than $17.75 per share. Analysts had expected approximately $17.86 per share for the full year — meaning UNH not only beat current-quarter estimates but also raised the bar for the entire year above where the Street was modeling it.
The market reacted with a swift vote of confidence. UNH shares surged nearly 7% on the news, a remarkable intraday move for a mega-cap stock of this scale.
Why the Medical Cost Ratio Was the Real Story
The number that arguably mattered most wasn’t EPS — it was the medical cost ratio (MCR), a metric that tells investors what percentage of premium revenue UnitedHealth is spending on actual medical care. A lower MCR generally signals better cost control and stronger profitability. UnitedHealth reported a Q1 2026 MCR of 83.9%, significantly better than the analyst consensus estimate of 85.70%. That 1.8-percentage-point beat on a metric this large translates directly into billions of dollars of better-than-expected profitability.
“We actually think we’re going to do a little bit better than we anticipated,” said company executive DeVeydt, who noted that while UnitedHealth still expects to lose 1.3 million Medicaid members, it is retaining somewhat more membership than previously projected. Optum Health, the company’s care delivery and technology arm, remains central to UnitedHealth’s long-term profitability strategy, even as it navigates Medicare Advantage plan exits across 109 counties.
The key takeaway: UnitedHealth is not just surviving its challenges — it is actively recalibrating and executing better than feared. For long-term investors in U.S. healthcare stocks, this was the most reassuring signal of the quarter.
GE Aerospace: Orders Explode, But the Stock Tells a Complicated Story
GE Aerospace came into this week as one of the most closely watched industrial names on Wall Street, and it did not disappoint on the headline numbers. The company reported Q1 2026 adjusted earnings per share of $1.86, a year-over-year increase of approximately 25% and a 15.5% beat over the Zacks Consensus Estimate of $1.61. Revenue came in at $11.6 billion, exceeding analyst forecasts of $10.71 billion by more than 8%.
But the truly jaw-dropping number? Orders. GE Aerospace’s total orders climbed 87% year over year to $23 billion in Q1 alone. To put that in perspective: commercial orders surged 93% year over year to $17.3 billion, while defense orders rose 67% to $6.2 billion. These are not incremental gains — this is a company experiencing an order-book explosion driven by the global aviation industry’s insatiable hunger for new jet engines and maintenance services.
The Engine Behind the Numbers
GE Aerospace’s Commercial Engine Services (CES) division was a standout performer, with revenues rising 34% as airlines aggressively sought maintenance, repair, and overhaul services for their existing fleets — a direct consequence of strong global air travel demand. The Defense Propulsion and Technologies division also posted significant gains, benefiting from growing U.S. and international defense budgets.
So why did GE’s stock dip 3.16% in premarket trading despite all of this? The answer lies in operating margins. Inflation and strategic investment costs squeezed margins during the quarter, creating a gap between revenue growth and profit expansion that unnerved some investors. Additionally, geopolitical uncertainties around supply chains and export controls added a layer of caution. GE Aerospace still confirmed expectations for low-double-digit revenue growth for 2026, a bullish outlook by any measure.
The verdict on GE Aerospace: a genuine operational powerhouse that is winning the aviation boom — but investors are demanding margin discipline alongside top-line growth. If the company can close that gap in Q2 and Q3, it will silence the skeptics.
RTX: The Clearest Winner of the Week
If one company deserved the title of “the week’s most complete earnings report,” it was RTX. The Arlington, Virginia-based aerospace and defense giant delivered a performance that checked every box Wall Street wanted to see: revenue beat, EPS beat, raised full-year guidance, and a confident management tone.
RTX reported Q1 2026 sales of $22.1 billion, up 9% versus the prior year and up 10% organically — a distinction that matters because it excludes the effects of currency fluctuations and acquisitions. Adjusted EPS came in at $1.78, up 21% year over year, crushing FactSet’s estimate of $1.51 per share — a 17% earnings surprise. Revenue also topped expectations of $21.47 billion. RTX generated operating cash flow of $1.9 billion and free cash flow of $1.3 billion during the quarter.
Then came the guidance raise — the number that sent shares climbing more than 2% in premarket trading.
RTX Raises the Bar for All of 2026
RTX updated its full-year 2026 outlook with meaningful increases across the board. The company now projects adjusted sales of $92.5 to $93.5 billion, up from the prior range of $92.0 to $93.0 billion. More significantly, it raised adjusted EPS guidance to $6.70 to $6.90 per share, up from $6.60 to $6.80. Free cash flow guidance of $8.25 to $8.75 billion was confirmed.
“RTX delivered a very strong start to 2026 with organic sales and adjusted operating profit growth across all three segments, driven by our continued focus on execution and delivering our backlog,” said RTX Chairman and CEO Chris Calio. The company’s total backlog now stands at an extraordinary $271 billion, including $162 billion in commercial orders and $109 billion in defense.
The performance across business units was equally impressive. Sales at the Raytheon defense unit rose 10%, and sales at the Pratt and Whitney jet-engine unit climbed 11%. Both divisions are benefiting from converging tailwinds: post-pandemic aviation recovery and accelerating global defense spending in the wake of ongoing geopolitical tensions. RTX is uniquely positioned to capture both trends simultaneously, and Q1 2026 proved the company is executing on that dual mandate with precision.
The Backlog as a Strategic Moat
RTX’s $271 billion backlog is not just a financial metric — it is a statement of strategic durability. A backlog of that scale means the company has years of revenue largely already secured, insulating it from short-term demand shocks. For investors seeking stability in uncertain markets, RTX’s combination of earnings growth, guidance raises, and an enormous backlog makes a compelling case. This was unquestionably the strongest overall report of the week.
3M: Quietly Reassuring in a Noisy Market
3M did not generate the same dramatic headlines as UNH or RTX this week, but make no mistake — its performance carried real significance. The St. Paul, Minnesota-based conglomerate reported Q1 2026 adjusted earnings of $2.14 per share, exceeding Wall Street’s estimate of $1.98 per share. The company’s profit beat was driven by higher demand for its industrial products and office supplies, signaling that 3M’s strategic pivot toward higher-growth markets is beginning to yield tangible results.
3M’s stock reacted positively, jumping in early trading — a validation that the market appreciated the beat even amid macro headwinds. Critically, the company reiterated its full-year 2026 adjusted earnings and revenue growth forecasts, sending a calm and confident message to investors in a week full of uncertainty.
A Conglomerate in Transition
3M has been undergoing one of the most significant strategic transformations in its 120-year history. After spinning off its healthcare division and settling massive legal liabilities, the new 3M is a leaner, more focused industrial company. Its Q1 2026 results suggest that the new strategy — prioritizing higher-growth markets and accelerating new product introductions — is gaining traction. In a volatile economy where many industrial companies are stumbling, 3M holding its ground and beating EPS expectations is a quiet but meaningful statement.
One important nuance: while adjusted EPS beat estimates, 3M’s net income declined on a GAAP basis compared to the prior year, impacted by one-time charges. Investors watching the headline profit figures saw a reported first-quarter profit of $653 million, or $1.23 per share, reflecting the drag from these charges. The divergence between adjusted and GAAP results is worth watching in future quarters, as it speaks to the ongoing cost of the company’s restructuring and litigation resolutions.
Still, the big picture for 3M is cautiously positive. The company is no longer the sprawling, unfocused conglomerate it once was. It is leaner, more disciplined, and beginning to produce results that match its new strategic identity.
What This Earnings Week Means for Investors
Stepping back from the individual company reports, this earnings week delivered a powerful collective message: large-cap American companies with real economic exposure — to healthcare, aviation, defense, and industrial manufacturing — are performing well. They are not just surviving macro headwinds; many are accelerating through them.
Here are the key investor takeaways from this week’s reports:
- Defense and aerospace are in a secular growth cycle. Both RTX and GE Aerospace are benefiting from dual tailwinds — commercial aviation recovery and rising global defense budgets. RTX’s $271 billion backlog and GE’s 87% order surge confirm this is not a temporary bounce.
- UnitedHealth’s turnaround is real, not a mirage. The MCR beat was not luck — it reflects deliberate cost management and improved government reimbursements. Investors who wrote off UNH after its 2025 struggles may need to reassess.
- 3M’s transformation is a slow-burn story. The conglomerate will not turn heads with explosive growth, but its ability to beat estimates and hold guidance in a volatile macro environment is precisely the kind of consistency long-term investors value.
- Guidance raises are the real signal. Both RTX and UnitedHealth raised their full-year outlooks — a rare and meaningful signal that management teams have high confidence in their trajectory, not just in one quarter, but for the year ahead.
The Bigger Picture: Why Earnings Season Matters Right Now
We are living through a period of genuine economic complexity. Tariff uncertainty, shifting federal healthcare policy, fluctuating interest rates, and geopolitical tensions are all real forces that affect corporate America every single day. Against that backdrop, an earnings week like this one — where four major American companies not only met but exceeded expectations — carries outsized psychological importance for markets.
When the Dow Jones Industrial Average components and S&P 500 heavyweights deliver strong results, it reinforces the thesis that the U.S. corporate sector remains fundamentally resilient. It does not eliminate risk, but it reframes the narrative from “how bad will it get?” to “how strong can it stay?”
For individual investors, this week’s results are a reminder that diversification across sectors — healthcare, defense, industrials, aerospace — can provide stability that no single trade or theme can offer. UNH, GE, RTX, and 3M each operate in distinct markets, face distinct challenges, and yet all four managed to deliver positively surprising results in the same week. That is not a coincidence — it is evidence of genuine earnings breadth across the U.S. economy.
Final Scorecard: Who Won, Who Surprised, Who to Watch
| Company | Q1 EPS (Actual) | EPS Estimate | Beat/Miss | Guidance Action | Biggest Story |
|---|---|---|---|---|---|
| UnitedHealth (UNH) | $7.23 | $6.57 | +$0.66 beat | Raised full-year to >$18.25 | MCR of 83.9% vs. 85.7% estimate |
| GE Aerospace (GE) | $1.86 | $1.61 | +$0.25 beat | Confirmed low-double-digit rev. growth | Orders surged 87% to $23B |
| RTX (RTX) | $1.78 | $1.51-1.52 | +$0.26-0.27 beat | Raised EPS to $6.70-$6.90 | $271B backlog; 21% EPS growth |
| 3M (MMM) | $2.14 | $1.98 | +$0.16 beat | Reiterated 2026 guidance | Industrial demand offsetting charges |
RTX took the top honors this week for its comprehensive beat-and-raise performance across all three business segments. UnitedHealth delivered the biggest shock — not just because of the EPS beat, but because the MCR improvement directly contradicts the bearish narrative that dominated UNH discussions for the past year. GE Aerospace proved it is an order-generation machine, even if margin work remains ahead. And 3M showed that quiet consistency, in this market, is its own kind of win.
Earnings season is far from over — Tesla, IBM, and Intel are also reporting this week — but for investors focused on the foundational pillars of the American economy, this week’s results from UnitedHealth, GE Aerospace, 3M, and RTX delivered exactly the kind of evidence needed to maintain conviction heading into the rest of 2026.
This article is for informational purposes only and does not constitute financial advice. Always consult a qualified financial advisor before making investment decisions.
